Curated News
By: NewsRamp Editorial Staff
July 29, 2025
Nicholas Focil Appointed President of hyperCORE International
TLDR
- Nicholas Focil's appointment as hyperCORE International's new president leverages his extensive experience to enhance the company's global clinical research leadership and strategic market expansion.
- hyperCORE International appoints Nicholas Focil as president, bringing decades of clinical operations leadership to optimize the network's efficiency and standardization across 80 trial sites.
- With Nicholas Focil at the helm, hyperCORE International aims to advance ethical, diverse clinical research, improving patient care and outcomes globally through innovative trials.
- Nicholas Focil, a leader in clinical research with a Nobel laureate collaboration background, takes the presidency at hyperCORE International to drive future innovations.
Impact - Why it Matters
This leadership change at hyperCORE International signifies a pivotal moment for clinical research, emphasizing the importance of diversity, quality, and innovation in trials. Focil's extensive experience and vision for expanding clinical research capabilities could lead to more inclusive and efficient studies, ultimately accelerating the development of new treatments and therapies for patients worldwide. The focus on ethical research and operational excellence underlines the critical role of clinical trials in advancing healthcare.
Summary
hyperCORE International, a leading clinical trial site network, has announced Nicholas Focil as its new president, marking a significant leadership transition. Focil, the founder and CEO of FOMAT Medical Research, brings nearly two decades of expertise in clinical operations and a strong commitment to diversity and quality in clinical research. His appointment is expected to further hyperCORE's mission of conducting ethical, high-quality clinical trials across North America and beyond. The network, known for its operational excellence and innovation, has completed over 7,000 studies with more than 140,000 participants. Focil's leadership is anticipated to enhance site capabilities and expand the reach of clinical trials, benefiting both patients and sponsors.
Outgoing president Carlos Orantes praised Focil's appointment as a milestone for hyperCORE, highlighting the network's continued path of excellence under new leadership. Focil expressed gratitude for Orantes's contributions and outlined his vision for advancing clinical research through collaboration and innovation. hyperCORE International's commitment to safe, ethical, and timely studies remains unwavering, with Focil at the helm steering the network through a dynamic period of growth in the clinical research industry.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, Nicholas Focil Appointed President of hyperCORE International
